Epirium

Epirium is a clinical-stage biopharmaceutical company that has developed unique insights related to the biology of mitochondrial biogenesis and tissue function, potentially resulting in novel therapeutic approaches to currently intractable neuromuscular diseases. The company has identified and established an IP-protected platform of small molecules that constitute a new class of therapeutics with the potential to stimulate mitochondrial biogenesis and tissue regeneration. Epirium is currently planning clinical trials with its initial drug candidate in Becker muscular dystrophy. To learn more, please visit http://www.epirium.com/. Headed by a seasoned team of industry veterans with decades of experience building and leading clinical and commercial...

Biopharmaceuticals,neuromuscular diseases,clinical operations,and drug product development

Epirium operates in the Pharmaceutical manufacturing industry.

Epirium's revenue is 1m - 10m

Epirium has 11 - 50 employees.